David J Mazzo Caladrius Biosciences, Inc. (CLBS) insider trading activity

David J Mazzo is President & CEO of CALADRIUS BIOSCIENCES, INC.. Currently has a direct ownership of 211,834 shares of CLBS, which is worth approximately $745,655. The most recent transaction as insider was on Oct 01, 2024, when has been sold 26,964 shares (Common Stock) at a price of $2.93 per share, resulting in proceeds of $79,004. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 212K

21.21% 3M change

119.42% 12M change

Total Value Held $745,655

David J Mazzo Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 01 2024	SELL Payment of exercise price or tax liability	$79,004 $2.93 p/Share	26,964 Reduced 11.29%	211,834 Common Stock
Oct 01 2024	BUY Grant, award, or other acquisition	$169,940 $2.93 p/Share	58,000 Added 19.54%	238,798 Common Stock
Jan 11 2024	SELL Payment of exercise price or tax liability	$3,067 $2.99 p/Share	1,026 Reduced 0.58%	174,766 Common Stock
Jan 10 2024	SELL Payment of exercise price or tax liability	$10,410 $3.0 p/Share	3,470 Reduced 1.94%	175,792 Common Stock
Jan 09 2024	SELL Payment of exercise price or tax liability	$61,741 $3.08 p/Share	20,046 Reduced 10.06%	179,262 Common Stock
Jan 09 2024	BUY Grant, award, or other acquisition	-	94,000 Added 32.05%	199,308 Common Stock
Jan 13 2023	SELL Payment of exercise price or tax liability	$1,449 $3.65 p/Share	397 Reduced 0.41%	96,543 Common Stock
Jan 11 2023	SELL Payment of exercise price or tax liability	$3,296 $3.2 p/Share	1,030 Reduced 1.05%	96,940 Common Stock
Jan 10 2023	SELL Payment of exercise price or tax liability	$11,069 $3.19 p/Share	3,470 Reduced 3.42%	97,970 Common Stock
Jan 09 2023	SELL Payment of exercise price or tax liability	$23,535 $3.0 p/Share	7,845 Reduced 7.18%	101,440 Common Stock
Jan 09 2023	BUY Grant, award, or other acquisition	-	60,000 Added 35.44%	109,285 Common Stock
Sep 01 2022	SELL Payment of exercise price or tax liability	$34,871 $0.5 p/Share	69,742 Reduced 8.62%	739,444 Common Stock
Sep 01 2022	BUY Grant, award, or other acquisition	$75,000 $0.5 p/Share	150,000 Added 15.64%	809,186 Common Stock
Jan 14 2022	SELL Payment of exercise price or tax liability	$5,421 $0.82 p/Share	6,611 Reduced 1.04%	631,065 Common Stock
Jan 13 2022	SELL Payment of exercise price or tax liability	$5,242 $0.81 p/Share	6,471 Reduced 1.0%	637,676 Common Stock
Jan 11 2022	SELL Payment of exercise price or tax liability	$14,564 $0.87 p/Share	16,740 Reduced 2.53%	644,147 Common Stock
Jan 10 2022	SELL Payment of exercise price or tax liability	$51,897 $0.92 p/Share	56,410 Reduced 7.86%	660,887 Common Stock
Jan 10 2022	BUY Grant, award, or other acquisition	-	401,000 Added 35.86%	717,297 Common Stock
Jan 14 2021	SELL Payment of exercise price or tax liability	$9,260 $1.56 p/Share	5,936 Reduced 1.94%	299,505 Common Stock
Jan 13 2021	SELL Payment of exercise price or tax liability	$43,729 $1.55 p/Share	28,212 Reduced 8.46%	305,441 Common Stock
Jan 13 2021	BUY Grant, award, or other acquisition	-	39,000 Added 10.47%	333,653 Common Stock
Jan 11 2021	SELL Payment of exercise price or tax liability	$26,427 $1.59 p/Share	16,621 Reduced 5.34%	294,653 Common Stock
Jan 11 2021	BUY Grant, award, or other acquisition	-	119,000 Added 27.66%	311,274 Common Stock
Jan 08 2021	SELL Payment of exercise price or tax liability	$7,562 $1.6 p/Share	4,726 Reduced 2.4%	192,274 Common Stock

Also insider at

PALI

PALISADE BIO, INC. Healthcare

Director

DJM

David J Mazzo

President & CEO

Basking Ridge, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CLBS shares.

Notify only if

Value

Insider Trading

Get notified when an Caladrius Biosciences, Inc. insider buys or sells CLBS shares.

Notify only if

Operation

Value

Type

News

Receive news related to CALADRIUS BIOSCIENCES, INC.

Track Activities on CLBS

Account